摘要
目的:探讨阿卡波糖及二甲双胍单独或联合应用治疗初诊2型糖尿病患者的临床效果。方法:选择63例初诊2型糖尿病患者,进行运动和饮食治疗的基础上,分别给予阿卡波糖(50mg,tid),二甲双胍(0.5g,tid)或两药联合治疗6个月,比较治疗前后所有患者的空腹血糖(FBS)、餐后血糖(PBS)、空腹胰岛素(FINS)、餐后胰岛素(PINS)、糖化血红蛋白(HbA1c)、血压(包括SBP和DBP)、腰围(WC)、血脂(包括TG、TC、HDL、LDL)、超敏c-反应蛋白(hs-CRP)等相关指标。结果:治疗6个月后,三组患者的FBS、PBS、FINS、PINS、HbA1c、SBP、DBP、血脂及hs-CRP均明显改善,二甲双胍组腰围及血脂改善优于阿卡波糖组,联合用药组在PBS、FINS、血脂及hs-CRP有协同作用。结论:联合应用阿卡波糖和二甲双胍治疗初发2型糖尿病患者可以弥补单用一种药物的局限,从而更有效的改善初诊2型糖尿病患者的糖脂代谢,血压及炎症反应情况,具有更好的临床治疗效果。
Objective：To observe the clinical effects of acarbose combined with mefformin in the treatment with newly diagnosed type 2 diabetes（T2DM） patients. Methods：63 cases of newly diagnosed T2DM patients were randomly assigned into 3 groups,namely one group was treated with aearbose alone, another group was treated with metformin alone, a third group was treated with mefformin combined with acarbose for 6 months. FBS, PBS, FINS ,PINS, HbAlc, blood pressure （including SBP and DBP） ,WC ,lipid profile（ including TG,TC,HDL,LDL） ,hs -CRP were compared before and after the treatment. Results： After 6 month treatment, FBS, PBS, FINS, PINS, HbA1 c, SBP, DBP, lipid profile and hs - CRP improved significantly （ P 〈 0.05 ）. Patients treated with mefformin had better performance in WC and lipid profile than those treated with aearbose. Combined treatment had additive effect on PBS,FINS,lipid profile and hs -CRP. Conclusion： Combination of acarbose and mefformin in treating newly diagnosed T2DM could compensate for the limitations of using either agent,leading to better glyeemie and lipid profile ,improved blood pressure control and inflammatory status ,which is of great clinical significance.
出处
《黑龙江医药》
CAS
2011年第2期223-225,共3页
Heilongjiang Medicine journal
